Boehringer Ingelheim celebrates 25 million applied doses of Bovela® with the efficacy of a live vaccine and the safety of an inactivated vaccine. A global milestone achieved that is a source of pride for the company and that represents the active collaboration in the elimination of persistently infected (PI) animals.
2007: THE ORIGIN
The origins of this vaccine date back to April 2007. On that date, the original Meyers study represents the starting point for the first double deletion vaccine. The study concludes that the vaccine does not inhibit the synthesis of interferon, does not cross the placenta and inhibits the pathogenicity of the virus.
2015: THE LAUNCH
Seven years later, in December 2014, marketing authorization was obtained for Bovela®, a vaccine that protects against BVD-1 and BVD-2; single dose, even in primary vaccination; from 3 months of age; applicable in pregnancy; and long protection (from 3 weeks to 12 months after vaccination).
Thanks to these characteristics, the vaccine provides great benefits such as safety, efficacy and convenience of use.
It is in March 2015 when Bovela® is launched in the Spanish and European markets for dairy, extensive and fattening cattle. A month later, the first agreements with institutions in Galicia are established, increasing confidence in the vaccine.
2015 TO 2020: REPORTS AND STUDIES ENDORSE THE EFFECTIVENESS
Between 2015 and 2018, the vaccine obtains a favorable evaluation in the periodic reports regarding efficacy, recommendations for use and safety. Good news that was reinforced in March 2017, when, for the first time, a vaccine against BVD demonstrated its ability to generate complete immunity, both humoral and cellular, and to generate a memory response.
In September 2020, after having renewed the marketing authorization a year earlier, a retrospective study was carried out on the effects of vaccination with Bovela® in situations of epidemic BVD in the BVD control program in Galicia. Their results show the increase in fertility and milk production, as well as the decrease in the duration of the outbreak.
One month later, the ADVANCE European Study on the increase in milk production in farms with endemic BVD and vaccinated with Bovela® up to +1.8 L/d is presented.
Over the years Bovela® has become the leading vaccine against BVD in Spain thanks to its excellent safety profile, 100% fetal protection (protection against BVDV-1 and BVDV-2) and prevention of birth of PI calves.
2023: 25 MILLION DOSES
This long road has led Boehringer Ingelheim to reach the figure of 25 million applied doses of BOVELA® worldwide. A fact that reinforces the leadership position of the vaccine and its broad projection.
2023-07-03 11:57:14
#Boehringer #Ingelheim #reaches #million #applied #doses #Bovela
